Articles tagged "Immunosuppression"

2022 American Transplant Congress
Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial
A. Ajlan¹, H. Aleid¹, T. Ali¹, H. Joharji¹, Z. Alabdulkarim¹, T. Aburiash¹, K. Almeshari¹, A. Nazmi¹, Y. Shah¹, E. Devol¹, D. Alkortas¹, D. Broering¹, I. Alahmadi¹, A. Ullah¹, A. Alotaibi¹, A. Aljedai²
¹KFSHRC, RIYADH, Saudi Arabia, ²MOH, RIYADH, Saudi Arabia
*Purpose: To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC…
2022 American Transplant Congress
Impact of Belatacept on Clinical Outcomes in Lung Transplant Patients with Antibody-Mediated Rejection
L. Zaffiri, R. Hallak, S. Leonard, M. Neely, A. Hulber, H. Berry, K. A. Young, J. M. Reynolds
Duke University, Durham, NC
*Purpose: Antibody-mediated rejection (AMR) is cause of significant morbidity and mortality in lung transplant recipients (LTRs). An optimal therapeutic regimen is still lacking. Recent evidence…
2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
P. A. Jacobson¹, A. Saqr¹, M. Al-Kofahi¹, D. P. Schladt², W. Guan³, W. S. Oetting¹, R. Mannon⁴, C. R. Dorr⁵, R. P. Remmel¹, G. C. Onyeaghala⁶, B. Wu³, A. K. Israni⁷, A. Matas⁸
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Hennepin Health Research Institute, Minneapolis, MN, ³Univ of MN, Biostatistics, Minneapolis, MN, ⁴Univ of Nebraska, Dept of Medicine, Omaha, NE, ⁵Hennepin Health Research Institute and Dept of Medicine, Minneapolis, MN, ⁶Hennepin Healthcare Research Institute, Minneapolis, MN, ⁷Hennepin Health Dept of Medicine and Univ of MN, Minneapolis, MN, ⁸University of MN, Dept of Surgery, Minneapolis, MN
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…
2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…
2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
E. Siskind¹, J. Splinter¹, C. Taing¹, A. Adekile², S. Njim¹, S. Shah¹, R. Plews³, D. Conti⁴, S. Patel²
¹Center for Transplantation, University Medical Center of Southern Nevada, Las Vegas, NV, ²University Medical Center of Southern Nevada, Las Vegas, NV, ³Center for Transplantation, Albany Medical Center, Albany, NY, ⁴Albany Medical Center, Albany, NY
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…
2021 American Transplant Congress
Characterizing Kidney Transplant Recipients with SARS-CoV-2: An Academic Single Center Experience
S. Nahi, A. Shetty, S. Tanna, J. Leventhal
Northwestern University, Chicago, IL
*Purpose: Kidney transplant (KTx) recipients are a unique cohort in regard to SARS-CoV-2 susceptibility and clinical course, owing to their immunosuppressed state and propensity for…
2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
T. Carcella, F. Bartlett, N. Patel, V. Rohan, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
2021 American Transplant Congress
Extreme Phenotype Sampling and Next Generation Sequencing to Identify Genetic Variants Associated with Tacrolimus Metabolism in African American Kidney Transplant Recipients
C. R. Dorr¹, B. Guo², B. Wu², J. Abrahante², D. Schladt³, R. Remmel², W. Guan², A. Muthusamy³, G. Onyeaghala³, N. Pankratz², A. Matas², R. Mannon⁴, W. Oetting², P. Jacobson², A. K. Israni³
¹Hennepin Healthcare Research Institute, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ⁴University of Nebraska Medical Center, Omaha, NE
*Purpose: Tacrolimus (TAC) pharmacogenomics studies identified common genetic variants that alter TAC troughs suggesting strategic dosing for specific populations. Common variants and clinical factors explain…
2021 American Transplant Congress
Adjuvant Treatment Shapes the Bone Marrow Myeloid Compartment Towards an Immunosuppressive Phenotype That Can Suppress Allograft Rejection
J. Ge¹, E. Anderson¹, J. F. Markmann², A. Cuenca¹
¹Surgery, Boston Children's Hospital, Boston, MA, ²Surgery, Massachusetts General Hospital, Boston, MA
*Purpose: Myeloid derived suppressor cells (MDSCs) expand in response to inflammatory stimuli and have been shown to suppress adaptive immunity. Preliminary data from our lab…
2021 American Transplant Congress
Influence of Immunosuppressant Management on Mortality in Kidney Transplant Recipients Hospitalized with COVID-19
Y. Fenig, A. Santeusanio, M. Menon, C. Liu, M. Rana, R. Shapiro
Mount Sinai Hospital, New York, NY
*Purpose: Kidney transplant recipients are thought to be at high risk for mortality from COVID-19 due to the necessity for chronic immunosuppressive therapy to prevent…